[go: up one dir, main page]

AR054909A1 - Modulacion de los receptores activados por el proliferador de peroxisomas - Google Patents

Modulacion de los receptores activados por el proliferador de peroxisomas

Info

Publication number
AR054909A1
AR054909A1 ARP060103503A ARP060103503A AR054909A1 AR 054909 A1 AR054909 A1 AR 054909A1 AR P060103503 A ARP060103503 A AR P060103503A AR P060103503 A ARP060103503 A AR P060103503A AR 054909 A1 AR054909 A1 AR 054909A1
Authority
AR
Argentina
Prior art keywords
peroxisom
prolifer
modulation
receptors activated
reductase
Prior art date
Application number
ARP060103503A
Other languages
English (en)
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of AR054909A1 publication Critical patent/AR054909A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)

Abstract

Un método para el tratamiento de una enfermedad relacionada con los receptores activados por los proliferados de peroxisomas mediante la administracion a un sujeto que lo necesita de una cantidad efectiva de un modulador del 15-ceto prostaglandin- delta13-reductasa. También se describen métodos para la identificacion de un compuesto para la inhibicion de la actividad de la reductasa y para reducir los niveles sanguíneos de glucosa mediante la administracion a un sujeto de una cantidad efectiva de un inhibidor de la reductasa.
ARP060103503A 2005-08-12 2006-08-10 Modulacion de los receptores activados por el proliferador de peroxisomas AR054909A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70789705P 2005-08-12 2005-08-12

Publications (1)

Publication Number Publication Date
AR054909A1 true AR054909A1 (es) 2007-07-25

Family

ID=37737230

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103503A AR054909A1 (es) 2005-08-12 2006-08-10 Modulacion de los receptores activados por el proliferador de peroxisomas

Country Status (16)

Country Link
US (1) US20070037193A1 (es)
EP (1) EP1803809A3 (es)
JP (1) JP2007061093A (es)
KR (1) KR20080014936A (es)
CN (1) CN1916167A (es)
AR (1) AR054909A1 (es)
AU (1) AU2006203479A1 (es)
BR (1) BRPI0603206A (es)
CA (1) CA2553115A1 (es)
CO (1) CO5780135A1 (es)
IL (1) IL177407A0 (es)
MX (1) MXPA06009161A (es)
NO (1) NO20063652L (es)
SG (1) SG130141A1 (es)
TW (1) TW200741003A (es)
ZA (1) ZA200606661B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2431634C2 (ru) * 2005-03-11 2011-10-20 Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин Соединения флавоноидов и их применение
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
AU2009259543B2 (en) * 2008-05-28 2015-09-03 Basf Se Means and methods for assessing increased peroxisomal proliferation
WO2010075280A2 (en) * 2008-12-22 2010-07-01 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds
EP2389459B1 (en) * 2009-01-21 2014-03-26 George Atanasoff Methods and systems for control of a surface modification process
EA015364B1 (ru) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения
CA2767616A1 (en) * 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
CN101948458B (zh) * 2010-09-07 2012-11-07 中国药科大学 具有抗肿瘤活性的黄芩素衍生物及在医药上的应用
CN102964322A (zh) * 2012-12-12 2013-03-13 中国药科大学 异黄酮或类黄酮脂肪醚类衍生物、其制备方法和医药用途
JP7029777B2 (ja) * 2016-03-28 2022-03-04 国立大学法人金沢大学 アンドロゲン依存性又は非依存性前立腺癌細胞の抑制用の組成物及びそれを含有する前立腺癌の医薬製剤
CN107496414A (zh) * 2017-09-21 2017-12-22 上海华堇生物技术有限责任公司 柽柳黄素的药物用途
CN112645922B (zh) * 2020-12-24 2022-01-07 中国人民解放军空军军医大学 香豆素类化合物、制备方法及应用
CN115894422A (zh) * 2022-12-26 2023-04-04 上海中医药大学 PPARγ激动剂及其组合和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543550B1 (fr) * 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
US4587260A (en) * 1984-06-21 1986-05-06 Warner-Lambert Company Dibenzalacetone and benzylcinnamate as non-steroidal anti-inflammatory compounds and compositions thereof
DE69130586T2 (de) * 1990-05-01 1999-06-17 R-Tech Ueno, Ltd., Osaka Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2181923T3 (es) * 1995-11-17 2003-03-01 Upjohn Co 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
EP1183370A2 (en) * 1999-05-20 2002-03-06 Incyte Genomics, Inc. Human oxidoreductase proteins
CN1443070A (zh) * 2000-03-24 2003-09-17 苏坎波公司 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物
AU2001251668A1 (en) * 2000-04-18 2001-10-30 Millennium Pharmaceuticals, Inc. 39228, a human alcohol dehydrogenase and uses therefor
WO2001080855A1 (en) * 2000-04-27 2001-11-01 Geron Corporation Telomerase inhibitors and methods of their use
US7326734B2 (en) * 2003-04-01 2008-02-05 The Regents Of The University Of California Treatment of bladder and urinary tract cancers

Also Published As

Publication number Publication date
CA2553115A1 (en) 2007-02-12
JP2007061093A (ja) 2007-03-15
CO5780135A1 (es) 2007-07-31
EP1803809A3 (en) 2007-12-19
TW200741003A (en) 2007-11-01
SG130141A1 (en) 2007-03-20
EP1803809A2 (en) 2007-07-04
MXPA06009161A (es) 2007-03-21
BRPI0603206A (pt) 2007-05-15
KR20080014936A (ko) 2008-02-15
ZA200606661B (en) 2008-05-28
NO20063652L (no) 2007-02-13
US20070037193A1 (en) 2007-02-15
IL177407A0 (en) 2006-12-31
AU2006203479A1 (en) 2007-03-01
CN1916167A (zh) 2007-02-21

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR054566A1 (es) Tratamientoombinado de los tumores que expresan el her
AR054909A1 (es) Modulacion de los receptores activados por el proliferador de peroxisomas
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
AR109263A2 (es) Composición que comprende moxidectina
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
GT200600426A (es) Formulacion novedosa
CR11486A (es) Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
CR9220A (es) Terapia combinatoria para el tratamiento de la diabetes y de condiciones relacionadas con la misma o para el tratamiento de condiciones mejoradas aumentando un nivel de glp-1 en sangre.
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
MX362693B (es) Composición para el cuidado oral para tratar y/o prevenir afecciones causadas por microorganismos, usando un dispositivo oral de luz.
DOP2011000188A (es) Compuestos de tiazolopiridinas moduladores de sirtuina
RU2009118942A (ru) Способ стимуляции регенерации тканей
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
UY29274A1 (es) Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida
UY30675A1 (es) Metodos para el tratamiento de la depresion
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
CO6311083A2 (es) 4-((1r,3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina para el tratamiento de la disfunción cognitiva
AR056500A1 (es) Metodo para preparar una composicion medica
AR049302A1 (es) Modulacion de receptores activados por proliferador de peroxisoma
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal